In a complicated case involving biotech patents for a high cholesterol treatment – and being closely watched by the patent world – the Supreme Court on Thursday affirmed the Federal Circuit and handed a major victory to Sanofi in its intellectual property battle with Amgen over Repatha, a treatment for high cholesterol.
Amgen sought to collect millions of dollars in damages from Sanofi and its partner, Regeneron Pharmaceuticals because Sanofi makes a rival drug called Praluent, which works by a similar mechanism as Repatha. Amgen initially sought a court injunction to force Praluent off the market, which was denied by an appeals court.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Jimmy Hoover
Jimmy Hoover covers the Supreme Court for The National Law Journal. He can be reached at [email protected]. Follow him on Twitter: @JimmyHooverDC.
